首页 | 本学科首页   官方微博 | 高级检索  
     


Long-term (48 weeks) effectiveness,safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
Authors:Piero Barbanti MD  PhD  Cinzia Aurilia MD  Sabina Cevoli MD  PhD  Gabriella Egeo MD  PhD  Luisa Fofi MD  Roberta Messina MD  Antonio Salerno MD  Paola Torelli MD  Maria Albanese MD  PhD  Antonio Carnevale MD  Francesco Bono MD  Domenico D'Amico MD  Massimo Filippi MD  Claudia Altamura MD  PhD  Fabrizio Vernieri MD  EARLY Study Group
Affiliation:1. Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy;2. IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy;3. Neurology Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy;4. San Giovanni Addolorata Hospital, Rome, Italy;5. Unit of Neurology, Department of Medicine and Surgery, Headache Center, University of Parma, Parma, Italy;6. Neurophysiopathology Unit, Headache Center, University Hospital of Rome “TorVergata”, Rome, Italy;7. San Filippo Neri Hospital, Rome, Italy;8. Center for Headache and Intracranial Pressure Disorders, Neurology Unit, A.O.U. Mater Domini, Catanzaro, Italy;9. Neuroalgology Unit, Headache Center Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milan, Italy;10. Headache and Neurosonology Unit, Policlinico Universitario Campus Bio-Medico, Rome, Italy
Abstract:
Keywords:allodynia  calcitonin gene-related peptide  erenumab  long-term treatment  migraine  sex
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号